{"id":12981,"date":"2021-05-23T16:55:21","date_gmt":"2021-05-23T14:55:21","guid":{"rendered":"http:\/\/miunidad.eu\/porib.com\/?page_id=12981"},"modified":"2024-05-30T11:21:05","modified_gmt":"2024-05-30T09:21:05","slug":"servicios-real-world-evidence","status":"publish","type":"page","link":"https:\/\/porib.com\/en\/servicios\/servicios-real-world-evidence\/","title":{"rendered":"Services Real-World Evidence"},"content":{"rendered":"

Health Economic Evaluation<\/span><\/h4>

Pricing and Reimbursement<\/span><\/h4>

Market Access<\/span><\/h4>

Real-World Evidence<\/span><\/h4>

Scientific Communication<\/span><\/h4>

Healthcare Management<\/span><\/h4>

Advisory Boards<\/span><\/h4>

Biostatistics<\/span><\/h4>

Training<\/span><\/h4><\/div>

\"\"
\nPORIB<\/strong> aims to demonstrate the efficiency<\/strong> of a health intervention, relating its cost and the health outcomes or benefits it brings to patients, their caregivers and society, through:<\/p>\n

    \n

    \n

  • Studies of resource consumption<\/strong> and cost analysis<\/strong>.<\/li>\n
  • Burden and cost of illness<\/strong> studies, from a health perspective or a social perspective (including costs related to labour productivity loss and informal care).<\/li>\n
  • Cost-minimization, cost-effectiveness, cost-utility and cost-benefit <\/strong>analysis.<\/li>\n
  • Cost-consequence <\/strong>analysis.<\/li>\n
  • Budget impact<\/strong> analysis<\/strong>.<\/li>\n
  • Modelling<\/strong> studies: decision analysis, Markov models, discrete event simulation, microsimulation and models with individual patient data.\n
      \n
    • De novo model design.<\/li>\n
    • Adaptation of models.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/div>

      \"\"<\/p>\n

      PORIB<\/strong> aims to achieve the value-based pricing of the drug or medical device and its public financing, for inclusion in the pharmaceutical provision, therefore PORIB is focused on:<\/p>\n

        \n
      • Development of value dossiers<\/strong> and clinical-economic evaluation<\/strong> reports for the therapeutic positioning of national (strategies for obtaining price and reimbursement) and regional (access) Health Authorities.<\/li>\n
      • Carrying out studies on the sensitivity<\/strong> of decision makers (stakeholders) to the price<\/strong> of medicines.<\/li>\n
      • Presentation of the necessary documentation<\/strong> to obtain the price and reimbursement of the health intervention. <\/li>\n
      • Strategic consulting<\/strong> and negotiation<\/strong> processes with the Ministry of Health during the drug pricing and reimbursement procedure.\n
      • Development of innovative<\/strong> financial or health outcome agreement programs<\/strong> (risk sharing, conditional financing, payment by results), to favour patient access to new health interventions.\n<\/ul>\n

         <\/p>\n<\/div>

        \"\"<\/p>\n

        Health interventions must demonstrate to the Health Authorities their level of innovation, socioeconomic value, incremental clinical benefit, therapeutic usefulness, cost-effectiveness and budgetary impact. For this purpose, PORIB<\/strong> delivers:<\/p>\n

          \n
        • Value dossiers <\/strong>and clinical-economic evaluation reports<\/strong> for Health Authorities, Health Technology Assesment bodies, and Pharmacy and Therapeutics Committees.<\/li>\n
        • Communication strategies<\/strong> and market access<\/strong> plans, mainly in particularly specific situations (onco-haematology, personalised medicine, and rare diseases).<\/li>\n
        • Interactive tools and models<\/strong>, adaptable to different scenarios, for direct use by Product Specialists, Medical Affairs or Medical Advisor, Key Account Managers and Institutional Relations Managers.<\/li>\n
        • Stakeholder mapping<\/strong> and landscape analysis<\/strong> studies.<\/li>\n
        • Risk-sharing<\/strong> and patient access programs<\/strong>.<\/li>\n
        • Multi-criteria decision analysis (MCDA).<\/strong> <\/li>\n
        • Healthcare benchmarking <\/strong>programs. <\/li>\n<\/ul>\n<\/div>

          \"\"<\/p>\n

          Information on the safety and efficacy of a health intervention must be complemented with effectiveness<\/strong>-based data to demonstrate the benefits of that intervention in the “real-world” (RWE), in routine clinical practice. For this purpose, PORIB<\/strong> develops:<\/p>\n

            \n
          • Effectiveness studies<\/strong>\n
              \n
            • Observational studies.<\/li>\n
            • Studies with pragmatic and naturalistic designs.<\/li>\n
            • Studies incorporating economic variables.<\/li>\n<\/ul>\n<\/li>\n
            • Epidemiological studies<\/strong>\n
                \n
              • Descriptive or analytical, cross-sectional or longitudinal, retrospective or prospective, observational or experimental studies.<\/li>\n
              • Studies of use, prescription, or treatment patterns.<\/li>\n<\/ul>\n<\/li>\n
              • Patient Reported Outcomes measures (PROm) and Patient-Reported Experience measures (PREm) studies <\/em><\/strong>\n
                  \n
                • Health-related quality of life.<\/li>\n
                • Preferences, by means of discrete choice experiments (DCE)<\/strong> and conjoint analysis (CA).<\/strong><\/li>\n
                • Satisfaction and expectations with treatment.<\/li>\n
                • Level of disability.<\/li>\n<\/ul>\n
                • Compliance studies<\/em><\/strong>\n
                    \n
                  • Adherence and persistence studies.\n
                  • Support and health education programs for patients.\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/div>

                    \"\"<\/p>\n

                    PORIB <\/strong> develops studies that review and synthesise the available clinical, economic, humanistic and social evidence<\/strong> on health interventions through:<\/p>\n

                      \n
                    • Literature research and systematic reviews.<\/strong><\/li>\n
                    • Meta-analysis<\/strong>.<\/li>\n
                    • Matching-adjusted indirect comparisons (MAIC), mixed-treatment comparisons (MTC) and network meta-analysis (NMA)<\/strong>.<\/li>\n
                    • Preparation, coordination and adaptation of clinical practice guidelines, consensus or recommendations<\/strong>, based on published scientific evidence.<\/li>\n<\/ul>\n

                      In addition, PORIB<\/strong> collaborates with experts in the development of documents describing the results of a health research, a scientific evidence study or an economic evaluation, through:<\/p>\n

                        \n
                      • Development and adaptation of articles<\/strong> for publication in scientific journals (in English and Spanish).<\/li>\n
                      • Preparation of abstracts, oral communications and posters<\/strong> for scientific congresses (in English and Spanish).<\/li>\n
                      • Preparation and adaptation of national and regional value dossiers<\/strong>.<\/li>\n
                      • Development, coordination and edition of reports, monographs and books.<\/strong><\/li>\n
                      • Critical review<\/strong> of published articles.<\/li>\n
                      • Design of materials (in graphic or digital format): case report forms<\/strong> for research protocols (paper or electronic), graphic materials<\/strong> for congresses, conferences, courses or seminars and development of user-friendly and interactive calculators<\/strong> for web and mobile (iPad, iPhone, and Android).<\/li>\n<\/ul>\n<\/div>

                        \"\"<\/p>\n

                        The efficient management of resources allows improving the response of the Healthcare System to the needs and preferences of patients and their caregivers (“patient centricity”), offering sustainable services that allow the adaptation to a greater demand for care, with an improvement in the productivity of the healthcare professionals. PORIB<\/strong> is involved in the development of:<\/p>\n